ArticleEuropean journal of pediatrics2026
Aspirin dose and coronary artery lesions in Kawasaki disease: a two-center retrospective comparative effectiveness study.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Coronary artery lesions (CAL) are the most common complication of Kawasaki disease (KD). Chinese guidelines recommend aspirin at 30-50 mg/kg/day during the acute phase, yet whether the dose within this range affects coronary outcome remains unclear. We retrospectively analyzed 997 children with complete or incomplete KD who received IVIG plus aspirin at two tertiary hospitals in Sichuan, China, from January 2017 to December 2025. Low-dose aspirin (30 to < 40 mg/kg/day; n = 630) was compared with high-dose (40 to 50 mg/kg/day; n = 367). Confounders were selected by intersecting a directed acyclic graph (Supplementary Fig. S1) with univariate screening at P < 0.10, yielding a final multivariable model of 7 predictors (136 CAL events; events-per-variable ratio of 19.4). Linearity of the continuous covariates and the absence of multicollinearity were verified (Supplementary Tables S1-S2). The dose-response relation was examined with restricted cubic splines, and inverse probability of treatment weighting (IPTW) was added as a sensitivity analysis. CAL at 4 weeks occurred in 13.5% of the low-dose group and 14.7% of the high-dose group (P = 0.658), with an adjusted OR of 0.94 (95% CI 0.64-1.38; P = 0.752). IVIG non-response was similar (4.1% vs 3.8%; P = 0.940), whereas aspirin-related adverse drug reactions were twice as frequent with high-dose aspirin (3.0% vs 6.3%; P = 0.021). The spline showed no significant linear (P = 0.253) or non-linear (P = 0.547) dose-response trend. IPTW yielded an OR of 0.95 (95% CI 0.65-1.38), and the doubly robust estimate was 0.95 (95% CI 0.65-1.40).
conclusionsWithin the guideline-recommended 30-50 mg/kg/day window, no significant differences were detected between low- and high-dose aspirin in coronary or IVIG non-response outcomes, while the lower dose halved adverse drug reactions. Although equivalence cannot be formally demonstrated in an observational study, these data suggest that 30 to < 40 mg/kg/day may be the preferable choice during the acute phase of KD in Chinese children. WHAT IS KNOWN: • Chinese guidelines recommend aspirin at 30-50 mg/kg/day during the acute phase of KD, yet comparative coronary outcome data within this dose range remain limited. WHAT IS NEW: • In a two-center cohort of 997 children, low-dose (30 to < 40 mg/kg/day) and high-dose (40 to 50 mg/kg/day) aspirin produced similar coronary artery lesion rates and IVIG non-response rates, whereas the lower dose halved the rate of adverse drug reactions.
Indexed as
Identifiers
42891855What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.